In 2024, the Food and Drug Administration (FDA) significantly invested in reorganizing its internal infrastructure and enhancing operations.
While Congress is renewing the priority review voucher program for rare pediatric diseases, the FDA should be required to ...
After the contentious Senate confirmation of Robert F. Kennedy Jr., another crucial governmental health leadership ...
FDA staffers tell CR how the suspension of their discretionary spending is threatening the safety of the American food supply ...
We all share the same goal—an efficient, effective FDA review process that helps advance the medical ... include staff ...
9don MSN
The meeting cancellation came one day before the CDC issued its weekly MMWR report, a scientific update on the latest ...
The reversal is the latest example of President Donald Trump and billionaire Elon Musk's chaotic approach to cost-cutting, ...
Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...
New SEC filings from pharmaceutical companies reveal Donald Trump and Elon Musk’s cost-cutting measures could slow drug ...
After hundreds of FDA employees were suddenly laid off last ... grow the agency’s staff toward the goal of reducing product review times. Layoffs led by the White House and the Department ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results